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ABSTRACT
Objectives To estimate the total number of cases of, and
cost of care for, genital warts (GWs) in England, to
inform economic evaluations of human papillomavirus
vaccination.
Methods The number of GW cases seen in general
practices (GPs) and in genitourinary medicine (GUM)
clinics was estimated using the General Practice
Research Database and the GUM Clinic Activity Dataset.
The overlap in care of cases in the two settings was
estimated. The calculated costs of care in GP and
hospitals were added to the costs of care in GUM clinics
(estimated elsewhere) to estimate the cost of care for
GWs in England.
Results In England, in 2008, GP and GUM saw 80531
new (157/100000 population) and 68259 recurrent
(133/100000 population) episodes, giving a total of
148790 episodes of care of GWs (289/100000
population). Seventy-three per cent of cases were seen
only in GUM clinics, 22% were seen by a GP before being
referred to GUM, and 5% by GPs only. Hospital care was
given in 1.3% of cases and contributed 8% of the costs.
The average cost of care per episode was £113, and the
estimated annual cost of care in England was £16.8
million.
Conclusions This study provides a fairly comprehensive
measure of GW frequency and care in England. GWs
exert a considerable impact on health services, a large
proportion of which could be prevented through
immunisation using the quadrivalent human
papillomavirus vaccine.
INTRODUCTION
Genital warts (GWs) are benign epithelial tumours
caused by infections with human papillomavirus
(HPV). They are the most common viral sexually
transmitted infection (STI) diagnosed among
genitourinary medicine (GUM) clinic attendees in
England, with w78000 newly diagnosed cases
reported by GUM clinics in 2009 (incidence of
newly GUM-diagnosed GW cases of 152/100000
population; 166/100000 male and 138/100000
female). Diagnosis rates are highest in 16e19 and
20e24-year-old women and men, respectively.
1
There are a number of home and clinic treatments
available, which can be long and painful and have
variable success rates.
2 GW recurrence is also
common, with w47000 diagnoses reported by
GUM clinics in 2009 (92/100000 population).
1
Two HPV vaccines are available for use in the
UKdone bivalent, the other quadrivalent. Both
vaccines have demonstrated protection against
HPV types 16/18, which cause over 70% of cervical
cancer cases in women.
3 4 The quadrivalent vaccine
additionally protects against HPV6/11 infections
and has been shown to prevent GWs in clinical
trials.
5 While reductions in disease due to HPV16/
18 may not be evident for many years, vaccinating
with the quadrivalent vaccine should result in
a quite rapid measurable reduction in GW inci-
dence. Australia introduced the quadrivalent
vaccine in 2007 for women under age 27, and, after
1 year, saw a decline of over 25% in women of this
age presenting with GWs at sexual health clinics,
67
as well as some herd-immunity effect in young
heterosexual men.
The potential savings to the health service from
GW prevention by the quadrivalent vaccine were
considered in the economic evaluation of vaccine
choice in 2007 in the UK.
8 At that point the
bivalent vaccine was chosen for the ﬁrst 3 years of
the immunisation programme,
9 and, since
September 2008, HPV16/18 vaccination has been
offered routinely to schoolgirls aged 12e13 years,
and a 2-year catch-up campaign has offered vacci-
nation to girls up to 18 years. By 2010, this
immunisation programme achieved a three-dose
coverage of over 84% in the routine and over 47% in
the 17e18-year-old catch-up cohorts.
10 The
delivery of HPV16/18 bivalent vaccine is not
expected to reduce the incidence of HPV6/11-
associated GWs, or other 6/11-related diseases
including recurrent respiratory papillomatosis and
some low-grade cervical lesions.
Here, we estimate the total numbers of GW
episodes seen in GUM clinics, GP, or both and
estimate an overall incidence of new GW episodes.
We also estimate the cost of GUM, GP and hospital
care for GWs in England.
METHODS
Annual incidence of GWs in England
Diagnoses made in two healthcare settings were
used to estimate the overall rate of GWs in
England: (1) episodes occurring between 2006 and
mid-2008 in the General Practice Research Database
(GPRD), which is a sentinel system that covers
w6% of patients registered with GPs in England
11;
(2) the GUM Clinic Activity Dataset (GUMCAD)
in 2008 and 2009, which collects data on all visits
and diagnoses in GUM clinics.
For all cases (ﬁrst and recurrent), we deﬁned an
episode of care as the period of time between the
ﬁrst and last attendance for that occurrence of
GWs, where the interval between attendances was
less than or equal to 8 weeks (56 days). This
interval was based on a recommendation by GUM
clinicians to allow for home treatment lasting for
4 weeks followed by a 4-week period for the patient
to re-attend with unresolved symptoms. The ﬁnd-
ings in a contemporaneous study of the clinical
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Health services researchrecords for GW cases in GUM clinics
12 that an episode of care
lasted, on average, 36 daysdthat is, well within our interval
perioddand that 87% of episodes had no intervals >8 weeks
(S C Woodhall, personal communication, 2010) validated this
clinical observation as the norm, and informed our sensitivity
analysis of longer intervals.
Consultations for GWs in GPRD data are not coded as new or
recurrent episodes, and, because of potential coding errors for GW
cases in GUM clinics, we deﬁned episodes of care for both
settings as new or recurrent on the basis of attendance history.
New episodes were deﬁned as the ﬁrst GW Read or OXMIS codes
per patient in GPRD (deﬁnition and list in the online appendix).
First episodes in GPRD were not necessarily new cases, as clinical
history for each patient varied from 1987 to 2008 and patients
may have had a GW diagnosis before this time, so our ‘new’
episodes in GP will be an overestimate of ‘new’ cases. In
GUMCAD, a ﬁrst episode began with the ﬁrst-attack code
(C11A), and, for patients with two or more C11A codes, those
subsequent codes were discounted (if within 8 weeks) or included
as recurrent episodes if occurring more than 8 weeks after the last
attendance. For GUM clinic episodes, the attendance dates of
recurrent (C11B) and persistent (C11C) warts and of uncoded
follow-ups were included. Follow-up visits within 8 weeks of
a previous visit were considered part of the same episode.
To estimate the annual number of GW episodes by age group
and sex, we combined data from GPRD and GUMCAD while
accounting for the overlap of episodes seen in GP and GUM
settings as follows. In GPRD, an episode with a referral code, or
at least one diagnostic code in the referral table, or an episode
with no treatment recorded was assumed to have been referred
to a GUM clinic. These episodes were used to provide an esti-
mate of the proportion referred from GP to GUM, by episode
type. A second referral estimate from a contemporaneous study
of GW care in GUM clinics was available for ﬁrst episodes
among GUM clinic attendees who reported a previous GP
consultation.
12 This was 42.3% (95% CI 38.3% to 46.3%) overall
and was available by sex and age group. Referral rates for
recurrent cases were not available from this study, and an overall
recurrent referral rate was approximated assuming that the same
number of patients was referred from GP to GUM as were
referred from GP to GUM according to GPRD. Similar referral
numbers were estimated for ﬁrst episodes from the two
approaches. We used an average of these two proportions, by
episode type, to estimate the number of episodes seen in both
GP and GUM. Rates of new and recurrent episodes per 100000
population were estimated using mid-2008 population ﬁgures
from the Ofﬁce of National Statistics. 95% CIs calculated for
these rates are not reported because they were too narrow to be
a meaningful representation of uncertainty.
Episodes of care in NHS hospitals were estimated from
hospital episode statistics (HES) for inpatients who had
a primary diagnosis of ICD-10 code A630 (anogenital (venereal)
warts) in 2008. Inpatient records included day cases admitted
and discharged on the same day. Repeat episodes of care were
those where the interval between attendances was >8 weeks. We
assumed that cases seen in hospitals were referred GP or GUM
clinic diagnoses, so these only added to the costs of GW care.
Costs of GW care
The cost of GP time per consultation was estimated to be £35
13
assuming an average consultation duration of 11.7 min.
14 The
additional costs of time for a treatment procedure were added as
5 min at £3/min (£15), making the total cost of GP time for
a consultation that required treatment to be £50. Unit costs for
treatments were based on estimates reported elsewhere.
12 The
mean cost per GP episode of care was determined by summing
the cost of all consultations and treatments given within the
episode for (1) episodes resolved by the GP and (2) episodes
referred to GUM with or without treatment, for which an
additional £94 (95% CI 84 to 104) was added for the cost of care
in GUM clinics.
12 For episodes only treated in GUM clinics, we
used £90 (95% CI 81 to 98) for ﬁrst episodes (male: £69, 95% CI
61 to 77; female: £111, 95% CI 97 to 124) and £107 (95% CI 79
to 134) for recurrent episodes (male: £108, 95% CI 70 to 146;
female: £105, 95% CI 65 to 144).
12 The method for determining
these costs for GUM care is described elsewhere.
12 The cost of
sexual health screens for GUM clinic attendees was not
included, nor the cost of any other care given at GP consultation.
We estimated the cost of tertiary care using the HRG4
2008e2009 Reference Cost Grouper package
15 and the NHS
national schedule of reference costs for 2008e2009.
16 The
Grouper produces a healthcare resource group (HRG) code for
each hospital episode, which we linked to the schedule of
reference costs and estimated national average hospital costs
with lower and upper quartiles. Costs also included excess bed
days and drug prescription costs. HRG codes that were unrelated
to GWs were excluded. The total annual cost of care for GWs
was estimated by combining total costs in all three settings.
Sensitivity analyses
We allocated uncoded follow-ups to other co-diagnosed STIs and
we varied the interval between attendances within an episode in
order to determine the impact of this on the number of recur-
rences and associated costs. The different intervals tested were
12, 16 and 24 weeks as the maximum plausible interval between
attendances within a single episode under care in the UK. Longer
intervals were considered more likely to cause errors of under-
estimation of episodes.
We also varied the assumption that no treatment recorded in
GP care implied a referral to GUM in 100% of such cases, instead
assuming only that 90% or 80% of such cases were referred to
GUM.
RESULTS
Impact of GWs in England
GP episodes of care
Between 2006 and mid-2008, there were 5243 episodes of care
for GWs in GPRD, of which 82% were new episodes. Fifty-one
per cent of episodes were among women, and the median age
(male and female) was 26 years (IQR 21e36). The majority of
episodes (89%) had one GP consultation only (range 1e17
consultations/episode), of which three-quarters were referred on
to GUM. For episodes that had two consultations (8%), the
median duration of episode of care was 12 days (range
2e57 days), and, for episodes with three or more consultations,
it was 48 days (range 4e331 days). Eighty-one per cent (95% CI
80 to 83) of ﬁrst and 43% (95% CI 39% to 46%) of recurrent
episodes were referred to GUM. Home treatment with
imiquimod (n¼357) or podophyllotoxin (n¼1147) was
prescribed more often than GP treatments (n¼326). There were,
on average, 2097 (95% CI 2041 to 2155) episodes of care/year,
and, after extrapolation to the total population under GP care in
England, the age-adjusted annual number of GW episodes seen
by GP was 39645 (32496 new and 7149 recurrent episodes).
GUM clinic episodes of care
There were 155389 new and 128149 recurrent cases of GWs
identiﬁed from GUM clinic data during 2008 and 2009, giving an
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Health services researchannual average of 141770 cases (77695 new, 64 075 recurrent).
Fifty-seven per cent of all cases were among men (slightly lower
for new episodes at 53%), and the median age of GUM attendees
was 25 years (IQR 21e33).
HES episodes of care
There were 1978 episodes of care for GWs in NHS hospitals in
2008. Of these, 1807 (91%) were ﬁrst episodes of hospital care
and 171 were repeat treatments. Fifty-nine per cent of episodes
were in men, and the median age was higher than for episodes
seen in GP and GUM settings (40 years, IQR 27e56), although
age was missing for 57%. Excision of perianal warts (40%) was
the most common operative procedure, followed by cauterisa-
tion or excision of lesions of the vulva (12%), anus (7%) and
penis (5%). For 87% of episodes, patients were admitted and
discharged on the same day. The maximum duration of hospital
stay for patients with a GW diagnosis alone was 5 days.
Incidence of anogenital warts in GUM and GP in England
Our estimate of having received care at both settings was 37%
for ﬁrst and 4% for recurrent episodes. On the basis of these
referral patterns, w30000 new and 3000 recurrent episodes
annually were seen by GP and subsequently by GUM (ﬁgure 1).
After this overlap had been accounted for, the total annual
number of GW cases was w149000. Fifty-three per cent of new
and 60% of recurrent episodes were in men. The estimated
incidence for all episodes was 289/100000 population, for new
episodes of GW, it was 157/100000 population, and the rate of
recurrences was 133/100000 population (ﬁgure 1). The incidence
of new episodes was 168/100000 and 142/100 000 population
among men and women (all ages), respectively, and peaked
among 20e24 year olds (755/100000 population) for both sexes
combined (ﬁgure 2).
Total cost of care for GWs in England
The average cost per episode of care resolved by GPs was £79 and
per episode seen by GP and GUM clinicians was £138. The
annual cost of care in GP and GUM, combined, was approxi-
mately £15.3 million. The average cost per episode of hospital
care was £718 and the annual cost of hospital care was
approximately £1.4 million. The estimated cost per episode of
care for all settings was £113 (95% CI 104 to 121). Costs were
higher for female than male patients. The estimated annual cost
of care for GWs in England, in GP, GUM and hospitals was £16.8
million (95% CI 15.5 to 18.0) (table 1).
Sensitivity analyses
Accounting for other STI diagnoses that could result in uncoded
follow-ups reduced the number of follow-ups attributable to
GWs and hence reduced the number of GWepisodes in GUM by
3% (to 130000). The number of recurrent episodes decreased
from 68000 to 60000 (ie, by 12%), 54000 (ie, by 21%) and
47000 (ie, 30%) when the interval between attendances within
an episode was increased from 8 weeks to 12, 16 and 24 weeks,
respectively. Changing the episode deﬁnition also increased the
cost of GP-only care from £79 (8 week deﬁnition) to £85 when
an interval of 24 weeks was used. Increasing the interval
between attendances had a greater impact on decreasing the
numbers of recurrent episodes than on increasing the cost per
episode treated by GPs, and resulted in a lowered total annual
cost of care to £14.7 million (95% CI 13.6 to 15.8)dthat is,
w10% lowerdfor an episode deﬁnition allowing 24-week
intervals.
Assuming that 10% or 20% of GP cases with no treatment
recorded were, in fact, not referred to GUM increased the
number only seen by GP (and total cases) by 1000e2000.
DISCUSSION
By combining analyses of data from GUM, GP and hospital, we
estimate w149 000 cases of GWs in England annually, at a cost
to diagnose and treat in the region of £17 million. Three-quarters
of cases were managed only in GUM clinics, a further ﬁfth were
seen in GP before being referred to a GUM clinic, and the
Figure 1 Estimated annual number of
genital wart (GW) diagnoses and rate per
100000 population in each setting by
episode type and sex. Numbers are
extrapolated to England using Ofﬁce of
National Statistics population data by sex,
while overall numbers are age adjusted and
do not equal sum of male and female
patients. *Rates are per 100 000
population. GP, general practice; GUM,
genitourinary medicine.
Figure 2 Estimated annual number of genital wart (GW) diagnoses per
100000 population in England by episode type and age group.
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Health services researchremainder (5%) were cared for by GP only. Hospital care was
given to 1% of all cases. The costs incurred by GUM, GP and
hospital services were 80%, 12% and 8%, respectively.
Our sensitivity analysis showed that our methods for esti-
mating the overlap between GP and GUM care may have
slightly (w1%) underestimated the total number of cases, while
our inclusion of uncoded follow-up visits and our method for
determining recurrent cases may have overestimated these (by
3% and up to 30%, respectively). Our estimates do not include
GW diagnoses and costs from a number of other health services
which provide sexual health screens in England, but for which
no surveillance data are currently available.
17 The HRG method
has not been previously used to estimate costs of GWs in
hospitals, and possible inclusion of unrelated operative codes and
other errors of the nature found in a study of diagnoses and
operative procedures for otolaryngology
18 may have caused over-
or under-estimation of hospital costs. Hospital costs may have
been underestimated by exclusion of GW codes other than the
primary diagnosis and of outpatient care. However, we under-
stand that the majority of hospital treatments register as ‘day
case’ inpatients in HES.
Our rates of GW episodes were broadly consistent with esti-
mates reported for the UK for 1998e2000 of GWs (new and
recurrent) in GP and GUM.
19 Our incidence of new and recur-
rent GWs in England is higher than reported from some other
European countries.
20e22 Australia has reported higher rates
without distinguishing new or recurrent cases,
23 while the
North American studies reported lower rates.
24e26 Differences in
the method used to determine recurrent cases probably
contribute to these differences (table 2). Higher rates in England
may also reﬂect higher-risk sexual behaviours, as evident from
higher rates of some other STIs and teenage pregnancies.
Our estimate for recurrent episodes is higher than that
reported by the Health Protection Agency for GUM clinics
Table 1 Estimated cost for episodes of care by gender, GPs, GUM clinics and hospitals*
n Males £ (95%CI) Females £ (95% CI)
Per episode (£)
(95% CI)
Total (£, in millions)
(95% CI)
GP only 7000 79 (75 to 83) 79 (76 to 82) 79 (77 to 82) 0.55 (0.54 to 0.57)
New episodes 3000 76 (72 to 77) 77 (73 to 81) 76 (73 to 79) 0.23 (0.22 to 0.24)
Recurrent episodes 4000 84 (77 to 90) 83 (78 to 88) 83 (79 to 88) 0.33 (0.32 to 0.35)
GP /GUM 33000 119 (107 to 130) 154 (139 to 169) 138 (127 to 148) 4.54 (4.18 to 4.89)
New cases 30000 118 (106 to 130) 153 (138 to 168) 132 (123 to 142) 3.97 (3.69 to 4.26)
Recurrent cases 3000 124 (112 to 136) 161 (146 to 176) 157 (128 to 185) 0.47 (0.39 to 0.55)
GUM onlyy 109000 80 (67 to 92) 109 (94 to 124) 94 (84 to 104) 10.25 (9.12 to 11.38)
New cases 48000 69 (61 to 77) 111 (97 to 124) 90 (81 to 98) 4.30 (3.89 to 4.72)
Recurrent cases 61000 108 (70 to 146) 105 (65 to 144) 107 (79 to 134) 6.51 (4.81 to 8.20)
Total GP and GUM 149000 n/cz n/cz n/cz 15.34 (14.16 to 16.52)
New episodes 81000 8.51 (8.00 to 9.01)
Recurrent episodes 68000 7.31 (5.62 to 9.00)
Hospitaldany 1978 724 (551 to 898) 714 (508 to 920) 718 (531 to 904) 1.42 (0.98 to 1.72)
Total of all settings 149000 97 (87 to 107) 129 (117 to 140) 113 (104 to 121) 16.76 (15.53 to 18.00)
*All ﬁgures have been rounded to the nearest 1000 and the total may not equal the sum of component costs.
ySource of GUM clinic episode costs: S C Woodhall, personal communication.
zNot calculated.
GP, general practice; GUM, genitourinary medicine; n/c, not calculated.
Table 2 Studies of genital wart (GW) incidence
Study Country, year
Interval for deﬁning
recurrence (months) Age and sex Episode type
Annual incidence/100000
population (95% CI)*
Presenty England, 2008e2009 2 (base case) All New 157
Recurrent 133
Sensitivity analyses 3 All Recurrent 116
4 All Recurrent 105
6 All Recurrent 91
Cassell et al
19 UK, 1998e2000 Not reported All All 307.6 (305.5 to 309.8) males
236.2 (234.2 to 238.4) females
Other studies of GW incidence
Castellsague ´ et al
20 Spain, 2005 Not reported 14e64 years New 117.86
Recurrent 42.57
Resistant 21.72
Hillemanns et al
21 Germany, 2005 Not reported 14e65-year-old females New 114 (109 to 119)
Recurrent 35 (32 to 37)
Lukasiewicz et al
22 France, 2000 Not reported All All 107
Pirotta et al
23 Australia, 2000e2006 Not reported All All 219 (188 to 249)z
Marra et al
24 Canada, 2006 12 >15 years All 126z
Hoy et al
25 USA, 2004 12 All All 120z
Insigna et al
26 USA, 2000 12 All All 165 (males) z
167 (females)
*95% CI are not presented for studies that did not report them.
y95% CIs calculated for the rates are not reported because they were too narrow to be a meaningful representation of uncertainty.
zAdapted from reported ﬁgures per 1000 population or person-years. Methods suggest denominator equivalent to population.
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Health services research(92/100000 population) partly because we included GP episodes
and deﬁned recurrence from attendance history, but also because
some episodes of care for re-registered persistent cases would
have been counted as recurrent cases. The combined rate of
persistent GWs reported by GUM clinics to the Health Protec-
tion Agency (29/100000) and recurrent GWs was more
comparable at 121/100000.
Costs for care of GWs have been reported from Spain
(V833),
20 Germany (V550)
21 and France (V342 females),
27 all in
2005, and from Australia (A$251, V178 for males and A$386,
V274 for females)
23 in 2009 and Canada ($C190, V139) in
2006.
24 Comparison with our cost of care per episode, for three
settings in England (£113 equivalent to V130, January 2011) is
not straightforward because of differences in settings studied
and case deﬁnitions, including episode duration.
Sexual health screens, which should be offered to all GUM
clinic attendees diagnosed with an STI, were not included in our
totals. On the basis of a cost of £52 per screen
28 this would cost
an additional £7.8m annually, bringing our total NHS cost to
over £24.6m.
GWs exert a considerable impact on health services in
England. These estimates of this impact should contribute to
assessing the potential beneﬁts of HPV vaccines that protect
against HPV6/11.
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Key messages
< In 2008, the estimated annual incidence of new episodes of
genital warts (GWs) was 157/100000 population, and the
rate of recurrent episodes was up to 133/100 000 population.
< The average cost of an episode of care for GWs (in
genitourinary medicine (GUM), general practice (GP) and
hospitals) was £113 (95% CI 104 to 121).
< The total annual cost of care for GWs in England was
approximately £16.8 million (95% CI 15.5 to 18.0), with over
three-quarters of these costs incurred in GUM clinics.
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